Vaishampayan UN. Core Evidence. 2014;9:61–67.
On page 62, line 6 of the Introduction section and page 67, line 2 of the Disclosure statement, “Exelexis Inc.” should read “Exelixis Inc.”.
. 2014 May 16;9:69. doi: 10.2147/CE.S67095
Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Collection date 2014.
© 2014 Vaishampayan. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
PMCID: PMC4032185
This corrects the article "Development of cabozantinib for the treatment of prostate cancer" on page 61.